UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------
FORM 8-K
----------------------
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
August 10, 2007
Date of Report (Date of earliest event reported)
----------------------
PRO-PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
----------------------
NEVADA 000-32877 04-3562325
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification No.)
7 WELLS AVENUE
NEWTON, MASSACHUSETTS
02459
(Address of Principal Executive Offices) (Zip Code)
(617) 559-0033
(Registrant's telephone number, including area code)
----------------------
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
--------------------------------------------------------------------------------
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On August 10, 2007, Pro-Pharmaceuticals, Inc. issued a news release regarding
its financial results for the quarter ended June 30, 2007. A copy of the news
release is being furnished as Exhibit 99.1 to this report.
The information in this report, including the Exhibit attached hereto, is
intended to be furnished and shall not be deemed "filed" for purposes of Section
18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 or the Exchange Act,
except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The list of exhibits called for by this Item is incorporated by reference
to the Index to Exhibits filed with this report.
--------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PRO-PHARMACEUTICALS, INC.
By: /s/ Carl L. Lueders
-------------------
Carl L. Lueders
Chief Financial Officer
Date: August 10, 2007
--------------------------------------------------------------------------------
EXHIBIT INDEX
Exhibit
Number Exhibit
--------------- ------------------------------------------------------------
99.1 Pro-Pharmaceuticals News Release- dated August 10, 2007,
furnished herewith